Close

Immunomedics (IMMU) to Terminate Phase 3 PANCRIT-1 w/ 90Y in Metastatic Pancreatic Cancer

March 14, 2016 4:31 PM EDT Send to a Friend
Immunomedics, Inc., (Nasdaq: IMMU) announced that the Company is terminating the Phase 3 PANCRIT-1 trial with yttrium-90-labeled (90Y) clivatuzumab tetraxetan ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login